We are live on ! Find out more
FBT icon

First Trust NYSE Arca Biotechnology Index Fund

236 hedge funds and large institutions have $860M invested in First Trust NYSE Arca Biotechnology Index Fund in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 70 increasing their positions, 79 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 22

1% more funds holding

Funds holding: 233236 (+3)

1.02% more ownership

Funds ownership: 46.07%47.09% (+1%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

5% less capital invested

Capital invested by funds: $908M → $860M (-$47.4M)

11% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 79

Holders
236
Holders Change
+3
Holders Change %
+1.29%
% of All Funds
4.13%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
28
Increased
70
Reduced
79
Closed
22
Calls
$1.81M
Puts
Net Calls
+$1.81M
Net Calls Change
+$999K

FBT Hedge Fund Activity: Q3 2021 in Review

236 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q3 2021, worth a combined $860M — down 5.2% from $908M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new FBT positions and 22 closed out — a net gain of 6 holders — while 70 added to existing stakes and 79 trimmed.

The largest buyer was Karp Capital Management, opening a new position worth an estimated $11.1M. The largest seller was Morgan Stanley, cutting an estimated $19.2M.

  • 236 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q3 2021, up from 233 in Q2 2021.
  • Funds reported $860M of First Trust NYSE Arca Biotechnology Index Fund stock for Q3 2021, down 5.2% quarter-over-quarter.
  • 28 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q3 2021 and 22 closed out, a net change of +6 holders.
  • The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q3 2021 was Karp Capital Management, an estimated $11.1M added.
  • The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q3 2021 was Morgan Stanley, an estimated $19.2M sold.

Based on aggregated 13F filings for Q3 2021.